Premium
Ten‐year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy
Author(s) -
Mikkola Arto,
Aro Jussi,
Rannikko Sakari,
Ruutu Mirja
Publication year - 2007
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20547
Subject(s) - medicine , prostate cancer , orchiectomy , prostate , urology , cancer , oncology , surgery
BACKROUND The aim of the study was to evaluate overall and prostate cancer (PCa) specific survival with special attention to cardiovascular (CV) mortality in patients primarily treated by parenteral polyestradiol phosphate (PEP) 240 mg/month or with orchiectomy (OE), taking into account the effect of pretreatment diseases and medication, and later PCa therapies. METHODS The present Finnprostate 6 study (10‐year follow‐up) consisted of 244 patients with locally advanced PCa (T3‐4 M0) and 200 patients with metastatic PCa (T1‐4 M1). Patients were randomized to OE or PEP therapy. The T3‐4 M0 and T1‐4 M1 patients were analyzed separately. RESULTS There was no difference in overall or PCa specific survival between the primary therapy groups in T3‐4 M0 or T1‐4 M1 patients. In the T3‐4 M0 patients the primary treatment (PEP vs. OE) was statistically significantly associated with a risk of CV deaths ( P = 0.001). Such an association was not found in the T1‐4 M1 patients. CONCLUSIONS The primary PEP and OE therapies are equal in terms of overall and PCa specific survival in patients with T3‐4 M0 or T1‐4 M1 disease. In T3‐4 M0 patients PEP increases the risk of CV deaths compared to OE but not in T1‐4 M1 patients. Prostate 67: 447–455, 2007. © 2007 Wiley‐Liss, Inc.